Next Article in Journal
The Attitude towards Vaccination of Health Sciences Students at a Spanish University Improved over the First 18 Months of the COVID-19 Pandemic
Next Article in Special Issue
Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia
Previous Article in Journal
SARS-CoV-2–Specific Vaccine Candidates; the Contribution of Structural Vaccinology
Previous Article in Special Issue
COVID-19 Vaccine Hesitancy and Associated Factors among Diabetes Patients: A Cross-Sectional Survey in Changzhi, Shanxi, China

Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine

School of Public Health, University of Haifa, Abba Khoushy 199, Haifa 3498838, Israel
Department of Health Systems Management, Max Stern Yezreel Valley College, Emek Yizreel 1930600, Israel
Rambam Medical Center, Haifa 3525408, Israel
Epidemiology Division, Israel Ministry of Health, Jerusalem 9446724, Israel
World Health Organization, European Region, 2100 Copenhagen, Denmark
Author to whom correspondence should be addressed.
Academic Editor: Zixin Wang
Vaccines 2022, 10(2), 233;
Received: 10 January 2022 / Revised: 26 January 2022 / Accepted: 30 January 2022 / Published: 3 February 2022
(This article belongs to the Special Issue COVID-19 Vaccination and Globe Public Health)
Background: The adverse events reported from the COVID-19 mRNA vaccines have varied from very mild, such as pain near the vaccination site, to more severe, with occasional anaphylaxis. Details of age-specific gender differences for the adverse effects are not well documented. Methods: Age and gender disaggregated data on reports of adverse events following two or three doses of the Pfizer-BioNTech COVID-19 vaccine were obtained from four cross-sectional studies. The first was from reports submitted to the Israel Ministry of Health national adverse events database (for ages 16 and above). The second was from a national cross-sectional survey based on an internet panel (for ages 30 and above), and the third and fourth were from cross-sectional surveys among employees of a large company (for ages 20–65) using links to a self-completed questionnaire. Results: In all studies, the risks of adverse events were higher following the second dose and consistently higher in females at all ages. The increased risk among females at all ages included local events such as pain at the injection site, systemic events such as fever, and sensory events such as paresthesia in the hands and face. For the combined adverse reactions, for the panel survey the female-to-male risk ratios (RRs) were 1.89 for the first vaccine dose and 1.82 for the second dose. In the cross-sectional workplace studies, the female-to-male RRs for the first, second and third doses exceeded 3.0 for adverse events, such as shivering, muscle pain, fatigue and headaches. Conclusions: The consistent excess in adverse events among females for the mRNA COVID-19 vaccine indicates the need to assess and report vaccine adverse events by gender. Gender differences in adverse events should be taken into account when determining dosing schedules. View Full-Text
Keywords: gender differences; COVID-19 vaccine; SARS-CoV-2; side-effects; adverse events gender differences; COVID-19 vaccine; SARS-CoV-2; side-effects; adverse events
Show Figures

Figure 1

MDPI and ACS Style

Green, M.S.; Peer, V.; Magid, A.; Hagani, N.; Anis, E.; Nitzan, D. Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine. Vaccines 2022, 10, 233.

AMA Style

Green MS, Peer V, Magid A, Hagani N, Anis E, Nitzan D. Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine. Vaccines. 2022; 10(2):233.

Chicago/Turabian Style

Green, Manfred S., Victoria Peer, Avi Magid, Neta Hagani, Emilia Anis, and Dorit Nitzan. 2022. "Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine" Vaccines 10, no. 2: 233.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop